Impact of low HER2 expression on response to CDK4/6 inhibitor treatment in advanced HR + /HER2- breast cancer: a multicenter real-world data analysis
In our analysis, HER2 status did not have a significant impact on treatment response to CDK4/6i.
Authors
- Carolin Müller (ORCID: https://orcid.org/0000-0003-3488-5073)
- A. Rambow (ORCID: https://orcid.org/0009-0005-4972-0177)
- Caroline Neeb
- Jens‐Uwe Blohmer (ORCID: https://orcid.org/0000-0002-7969-250X)
- Cornelia Kolberg‐Liedtke (ORCID: https://orcid.org/0000-0003-4526-3368)
- Erich‐Franz Solomayer (ORCID: https://orcid.org/0000-0002-2622-5676)
- Damian J. Ralser (ORCID: https://orcid.org/0000-0001-8916-7605)
- Alina Valik Abramian
- Verena Kiver (ORCID: https://orcid.org/0000-0002-1356-9576)
- Nicolaì Maass (ORCID: https://orcid.org/0000-0002-1430-4676)
- Florian Schütz (ORCID: https://orcid.org/0000-0002-2529-1591)
Institutions
- Cleveland Clinic (US)
- Outcomes Research Consortium (US)
- University Hospital Bonn (DE)
- Humboldt-Universität zu Berlin (DE)
- University Hospital Schleswig-Holstein (DE)
- Essen University Hospital (DE)
- Diakonissenkrankenhaus (DE)
- Saarland University (DE)
- University of Lübeck (DE)
Publication Details
- Journal
- Archives of Gynecology and Obstetrics
- Published
- 2024-10-07
- DOI
- https://doi.org/10.1007/s00404-024-07761-2
- Citations
- 5
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- Deutsche Forschungsgemeinschaft
- Rheinische Friedrich-Wilhelms-Universität Bonn